BioSpace News Archive

NPXe Limited announced that it has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

LIBRETTO-531 is first ever Phase 3 trial in RET-mutant medullary thyroid cancer

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza

Greiner brings to Avanos more than 20 years of experience in corporate finance, accounting, treasury and M&A strategy development and execution.

Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments

Updated anticipated timing for final results in its ongoing pivotal Phase 3 clinical trial of PRN1008 data in patients with pemphigus, as well as complete response rates from its Phase 2 Part B open-label trial.

Pivotal Phase 2/3 study is being conducted in collaboration with Children’s Oncology Group

More Than $1.8 Million Raised During Two Years as National Sponsor of NKF Kidney Walks

Molgradexvis an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of aPAP.

The Phase III, multi-center trial in China is designed to assess the efficacy, safety and pharmacokinetics of SCB-808 and originator drug Enbrel® in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) via subcutaneous administration.